Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To differentiate the quantitative sensory testing (QST) results of subjects simulating small and large fiber sensory loss from those of normal subjects and subjects with sensory peripheral neuropathy.
Background: QST is used to measure sensory thresholds in clinical, epidemiologic, and research studies. It is not known whether there are objective test results that characterize the subject seeking to deceive the examiner.
Methods: The Computer Aided Sensory Examination IV 4, 2, and 1 stepping algorithm was used to determine vibration and cold perception in nine naïve subjects. Subjects were asked to simulate sensory loss (on two occasions) and to respond normally on one occasion. Test results were compared to those of subjects with diabetic sensory neuropathy. Each QST trial was performed three times.
Results: Reproducibility, measured by the intraclass correlation coefficient, was similar in all groups for the vibration perception test (simulation 1: 0.68 [95% CI 0.31, 0.91], simulation 2: 0.82 [95% CI 0.54, 0.95], normal response: 0.77 [95% CI 0.47, 0.94], and subjects with peripheral neuropathy: 0.76 [95% CI 0.18, 0.95]) and the cold perception test (simulation 1: 0.53 [95% CI 0.12, 0.85], simulation 2: 0.82 [95% CI 0.55, 0.95], normal subjects: 0.67 [95% CI 0.30, 0.90] and subjects with peripheral neuropathy: 0.88 [95% CI 0.57, 0.97]), all just noticeable difference units. There were no differences between performance characteristics in the two simulation trials. Responses to null stimuli did not differentiate between groups.
Conclusion: Test performance characteristics do not permit discrimination among subjects simulating sensory loss, subjects with normal responses, and subjects with peripheral neuropathy.
- Received August 9, 2002.
- Accepted in final form October 8, 2002.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Special Article
Quantitative sensory testingReport of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyM.E. Shy, E.M. Frohman, Y.T. So et al.Neurology, March 25, 2003 -
Articles
Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathyM. J. Hilz, M. Brys, H. Marthol et al.Neurology, April 12, 2004 -
Articles
Evaluation of a clinical screening tool for HIV-associated sensory neuropathiesCatherine L. Cherry, Steven L. Wesselingh, Luxshimi Lal et al.Neurology, December 12, 2005 -
Articles
Residual neuropathy in long-term population-based follow-up of Guillain–Barré syndromeCharlotte Dornonville de la Cour, Johannes Jakobsen et al.Neurology, January 24, 2005